Webcast

CMV Prophylaxis in Kidney Transplant: Examining New Solutions to an Old Problem

Launch Date
11/29/2023 at 5:00 am EST
Credit Amount
1.0
Credit Expires
11/29/2024

Faculty

Daniel Kaul, MD
(Moderator)
Professor of Infectious Disease
Director of Transplant Infectious Disease
Program Director of ID Fellowship Program
University of Michigan Medical School
Ann Arbor, MI
Daniel Kaul, MD
(Moderator)

Daniel Kaul, MD, is a professor of internal medicine in the Division of Infectious Disease at the University of Michigan in Ann Arbor. He is the director of the Transplant Infectious Disease Service and the program director of the Infectious Disease Training Program. He has published widely on the management of cytomegalovirus in immunocompromised patients. Dr. Kaul serves on the program committee for the American Transplant Congress and is on the editorial board for the New England Journal of Medicine Journal Watch Infectious Disease. He has been the local principal investigator on numerous clinical trials of antiviral agents and has also conducted investigator-initiated trials.

Roy D. Bloom, MD
Professor of Medicine
University of Pennsylvania Perelman School of Medicine
Medical Director, Kidney and Pancreas Transplant Program
Hospital of the University of Pennsylvania
Philadelphia, PA
Roy D. Bloom, MD

Roy D. Bloom, MD, graduated from the University of Witwatersrand Medical School in Johannesburg, South Africa. Following his residency at Albert Einstein Medical Center in Philadelphia, Pennsylvania, he completed nephrology fellowship training at Harvard Medical School in Cambridge, Massachusetts and at the University of Pennsylvania in Philadelphia. He is a professor of medicine at the University of Pennsylvania and medical director of its Kidney and Pancreas Transplant Program. Dr. Bloom has mentored over 25 transplant nephrologists, several of whom now hold leadership positions in transplantation across the United States. His scholarly activity spans co-authorship of more than 200 publications, with areas of interest including transplant policy, viral infections in transplantation, biomarkers, clinical immunosuppression studies, and post-transplant outcomes.

Dr. Bloom has previously served on the American Society of Transplantation’s (AST) board of directors as well as most of that Society’s committees related to patient care, education, and practice improvement. He has been a member of various AST, Kidney Disease Improving Global Outcomes (KDIGO), and Kidney Disease Outcomes Quality Initiative (KDOQI) work groups. He has co-chaired the AST/American Society of Nephrology (ASN) Transplant Course and is an AST/ASN Transplant Nephrology Core Curriculum faculty member. He previously served as a transplant representative on the ASN Public Policy Board and is currently a member of the AST Public Policy Committee and the ASN transplant work group that advises ASN leadership. He is a founding member of the AST Medical Directors Task Force. He was a work group member of the AST Biomarker Consensus Conference in 2022 and recently co-chaired the AST Controversies Conference related to long-term care of transplant recipients.

Dr. Bloom currently serves on the Cutting Edge of Transplantation annual meeting planning committee. He is an associate editor for the American Journal of Kidney Diseases.

Margaret R. Jorgenson, PharmD, BCTXP
Clinical Pharmacist – Abdominal Solid Organ Transplant and Infectious Disease
CMV Antiviral Stewardship Program Lead
UW Health
Madison, WI
Margaret R. Jorgenson, PharmD, BCTXP

Margaret R. Jorgenson, PharmD, BCTXP, is a clinical pharmacist at UW Health in Madison, Wisconsin with 14 years of experience caring for abdominal transplant recipients. Dr. Jorgenson specializes in infectious diseases and has focused on optimizing patient outcomes through quality improvement. Her primary area of interest is treatment and prevention of cytomegalovirus (CMV) infection and disease.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Post-transplant cytomegalovirus (CMV) infection afflicts as high as 80% of kidney organ transplant recipients, resulting in life-threatening direct complications, long-term negative outcomes, and significant morbidity and mortality. Current first-line antivirals administered to patients in post-treatment prophylaxis are associated with toxicity that increases the risk of opportunistic infections and of graft rejection. Emerging therapies, however, have demonstrated lower toxicity rates in other disease states and present potential prophylaxis alternatives for the kidney transplant population. It is imperative that clinicians working in the transplant field are appraised on emerging therapies to provide the best possible standards of care.

In this CME Outfitters Live Webcast, expert faculty will guide learners through the implications of CMV infection as well as strategies to individualize and optimize CMV prevention in kidney transplant recipients. Faculty will also help learners to implement an interprofessional team approach, including institutional policies or protocols, to support optimal use of CMV prophylaxis therapies.

Learning Objectives

  • Identify the current implications of CMV infection in kidney transplant recipients
  • Develop evidence-based, individualized plans to optimize CMV prevention for kidney transplant recipients
  • Implement an interprofessional team approach including institutional policies or protocols to support optimal use of CMV prophylaxis therapies

Financial Support

Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Target Audience

Transplant specialists/surgeons, ID specialists, transplant and ID pharmacists, nurse practitioners (NPs), physician associates (PAs), hospitalists, internists, primary care physicians, and nurses

Credit Information

Jointly accredited provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit ( JA0007185-0000-23-134-H01-P ).

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 11/29/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Kaul reports the following financial relationships:

Research Support: AstraZeneca; Janssen Pharmaceuticals, Inc.; Nobelpharma America, LLC.; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Bloom reports the following financial relationships:

Research Support: CSL Behring; CareDX; Memo Therapeutics AG; Natera, Inc.; and Veloxis Pharmaceuticals, Inc.

Other financial or material support: Royalty: UpToDate, Inc.

Dr. Jorgenson reports no financial relationships to disclose.

Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:

  • Rebecca Vargas-Jackson, MD (peer reviewer)
  • Joshua Caballero, PharmD, BCPP, FCCP (peer reviewer)
  • Keshia Pitt, PhD (planning committee)
  • John Jones, PharmD (planning committee)
  • Kasey Brandt, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)
  • Joshua Caballero PharmD, BCPP, FCCP (Peer Reviewer)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WCV-079-112923-44

CMV Prophylaxis in Kidney Transplant: Examining New Solutions to an Old Problem
Event Date: 11/29/2023 at 5:00 am EST
Register

Related Activities

Virtual Education
11/16/2024 at 10:24 pm EST

How Low Can You Go? Targeting of Deep Remission in the Management of Crohn’s Disease

Learn More
Virtual Education
11/16/2024 at 10:24 pm EST

What’s IL-23 Got to Do With It? Targeted Therapies in the Management of IBD

Learn More